Freedland, Stephen J. http://orcid.org/0000-0002-8104-6419
Hong, Agnes
El-Chaar, Nader
Murty, Sharanya
Ramaswamy, Krishnan http://orcid.org/0000-0003-0890-0268
Coutinho, Anna D.
Nimke, David
Morgans, Alicia K. http://orcid.org/0000-0002-6563-4587
Funding for this research was provided by:
This study was funded by Astellas Pharma Inc. and Pfizer Inc., the co-developers of enzalutamide.
Article History
Received: 6 July 2022
Revised: 8 November 2022
Accepted: 17 November 2022
First Online: 14 December 2022
Competing interests
: SJF acted as a consultant for Astellas, AstraZeneca, Bayer, Janssen, Merck, Myovant, Pfizer, and Sanofi. AH was an employee of Astellas during the conduct of the study and reports ownership of stocks of CRISPR, Insmed, Intercept, Revance, and Veru. NEC was an employee of Astellas during the conduct of the study and reports ownership of stocks of BioNano Genomics, Recurson Pharmaceuticals, Sesen Bio, Soligenix, and Tonix Pharmaceuticals. SM has nothing to disclose. KR was an employee of Pfizer during the conduct of the study and reports ownership of stocks of Pfizer. ADC was an employee of Xcenda during the conduct of the study and reports ownership of stocks of AmerisourceBergen. DN was an employee of Astellas during the conduct of the study. AKM reports funding from Astellas during the conduct of the study; grants from Bayer, Myovant, Pfizer, and Prostate Cancer Foundation; honoraria from Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, Clovis, Exelixis, Genentech, Janssen, Merck, Myovant, Pfizer, Sanofi, and Telix; as well as travel support from Sanofi. AKM also reports research funding from Astellas, AstraZeneca, Bayer, Dendreon, Genentech, Myovant, Sanofi, and Seattle Genetics. AKM participated in advisory boards for Bayer and Myovant and acted as a consultant for Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, Blue Earth, Exelixis, Janssen, Lantheus Medical Imaging, Merck, Myovant, Myriad Genetics, Novartis, and Sanofi.